Is Rifaximin registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 2 valid registrations of Rifaximin, including XIFAXAN (550 mg, Film-coated tablet, SAR 1106.60); XIFAXAN 200MG F.C.TABLET (200 mg, Film-coated tablet, SAR 83.90).

Is Rifaximin approved by the US FDA?

Drugs@FDA lists 3 application product lines for Rifaximin, including XIFAXAN (Prescription); XIFAXAN (Prescription); RIFAXIMIN (Prescription).

Are there safety signals or safety updates for Rifaximin?

US FDA: 1 entry (latest 2023-10-19).

Active substance

Rifaximin

SFDA 2
US FDA 3
Health Canada 1
NHS prices 2
Safety 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
XIFAXAN	550 mg	Film-coated tablet · Oral use	56 Blister	SAR 1106.60	NCE · Prescription	Alfasigma S.p.A	Valid
XIFAXAN 200MG F.C.TABLET	200 mg	Film-coated tablet · Oral use	12 Blister	SAR 83.90	NCE · Prescription	Alfasigma S.p.A	Valid

Indications — CHI Daman Drug Formulary

IRRITABLE BOWEL SYNDROME

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
XIFAXAN	200MG; 550MG	tablet · oral	SALIX PHARMS	Prescription	25 May 2004
XIFAXAN	550MG	tablet · oral	SALIX PHARMS	Prescription	24 Mar 2010
RIFAXIMIN	550MG	tablet · oral	ACTAVIS LABS FL INC	Prescription	19 Mar 2026

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
ZAXINE	02410702	550 MG	TABLET · ORAL	SALIX PHARMACEUTICALS INC

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
NHS Drug Tariff	Rifaximin 200mg tablets	£15.15	9 tablet	1 Oct 2026
NHS Drug Tariff	Rifaximin 550mg tablets	£259.23	56 tablet	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Safety signals and safety-related labeling changes

US FDA 19 Oct 2023 XIFAXAN — safety-related labeling change
Labeling sections changed: Adverse Reactions; Drug Interactions

All safety entries for rifaximin →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.